Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy-Reference-Cited by-同舟云学术

Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy

Published:2021-11-03 Issue:21 Volume:64 Page:15716-15726
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

He Lei¹²,Wang Liangliang¹³,Wang Zhisong¹²,Li Tiantian¹,Chen Hui¹²,Zhang Yaning¹,Hu Zeping¹,Dimitrov Dimiter S.⁴,Du Juanjuan¹^ORCID,Liao Xuebin¹²^ORCID

Affiliation:

1. School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China

2. Advanced Innovation Center for Human Brain Protection, Beijing Tiantan Hospital, Capital Medical University, Beijing 100088, China

3. Department of Radiation and Cellular Oncology, The Ludwig Center for Metastasis Research, University of Chicago, Chicago, Illinois 60637, United States

4. Center for Antibody Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania 15216, United States

Funder

Roche

Ministry of Science and Technology of the People's Republic of China

National Natural Science Foundation of China

Tsinghua-Peking Centre for Life Science

Beijing Advanced Innovation Center for Human Brain Protection

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link